Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma

摘要: Replication conditional oncolytic human adenovirus has long been considered a promising biological therapeutic to target high-grade gliomas (HGG), group of essentially lethal primary brain cancer. The last decade witnessed initiation and some completion number Phase I II clinical investigations for HGG in the US Europe. Results these trials patients are pivotal not only federal approval but also filling an existing knowledge gap that primarily derives from stark differences permissivity between humans preclinical mouse models. DNX-2401 (Delta-24-RGD), current mainstream with modifications E1A fiber, shown induce impressive objective response long-term survival (>3 years) fraction recurrent HGG. Responders exhibited initial enlargement treated lesions few months post treatment, followed by shrinkage near complete resolution. In accord research, post-treatment specimens revealed virus-mediated alteration immune tumor microenvironment as evidenced infiltration CD8+ T cells M1-polarized macrophages. These findings encouraging together further information ongoing studies have potential make viable option management This review deals this timely topic; we will describe both development therapy HGG, summarize updated on discuss challenges field currently faces.